Safe Opioid Prescribing: A Patient-Centered Approach to the FDA Blueprint

A 3-part Series

Expiration Date: December 31, 2022

Learners can participate in one or more activities. Activities can be completed in any order.

Certifications (per activity)

1.0 AMA PRA Category 1 credit™

1.0 AANP credit

1.0 ACPE credit

1.0 ANCC credit

Estimated time to complete activity

1 hour

Statement of Need/Program Overview

The opioid crisis in the United States is now in its third decade. Over time, this crisis has been characterized by the overuse of opioid analgesics to control acute and chronic pain, explosive growth in the number of opioid-related overdoses and deaths, and more recently, a contraction in prescribing of opioid medications, as health care providers (HCPs) struggle to balance the benefits and risks of these powerful medications. Subsequently, the FDA issued risk evaluation and mitigation strategies (REMs) for extended-release/long-acting (ER/LA) and immediate-release (IR) opioids, along with a model for developing the HCP education mandated in these REMS: the FDA Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain. The purpose of this program is to educate HCPs on the safe prescribing of opioid analgesics as laid out in the FDA Blueprint.

Target Audience

The Managing Opioid Risk in Acute and Chronic Pain initiative is designed to reach health care professionals (HCPs) involved in the management of patients with pain and licensed to practice in the United States and its territories—particularly those professionals with a Drug Enforcement Agency (DEA) registration to prescribe Schedule II and III drugs.

Educational Objectives

After completing this activity, the participant should be better able to:

• Explain the need for comprehensive pain education
• Outline the fundamental concepts of pain management, including definitions and mechanisms of pain
• Assess patients in pain, including identifying risk factors for abuse and addiction
• Discuss the range of therapeutic options for managing pain, including nonpharmacologic approaches and pharmacologic (non-opioid and opioid analgesic) therapies
• Explain how to integrate opioid analgesics into a pain treatment plan individualized to the needs of the patient
• Review how to safely and effectively manage patients on opioid analgesics in the acute and chronic pain settings, including initiation and titration
• Discuss how to counsel patients and caregivers about the safe use of opioid analgesics, including storage and disposal and use in special populations
• Describe the use of naloxone for opioid overdose
• Review how to safely and effectively manage patients on opioid analgesics, including dose titration, opioid rotation, and tapering
• Specify when referral to a pain specialist is appropriate
• Identify and manage patients with opioid use disorder
• List the fundamental elements of addiction medicine
• Discuss how to counsel patients and caregivers about the safe use of opioid analgesics, including proper storage and disposal

Faculty

Chair

Presenters

Fee Information and Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and ACE do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

This activity is jointly provided by Global Education Group and Applied Clinical Education.

This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FSA).

This activity is distributed by CMEZone.com